Xtandi for Prostate cancer (castration-resistant and metastatic hormone-sensitive)
Quick answer: Xtandi is used for Prostate cancer (castration-resistant and metastatic hormone-sensitive) as part of a androgen receptor inhibitor treatment regimen. Non-steroidal androgen receptor antagonist that blocks androgen binding, nuclear translocation, and DNA interaction The specific dosing for Prostate cancer (castration-resistant and metastatic hormone-sensitive) is determined by your prescriber based on individual factors.
Why is Xtandi used for Prostate cancer (castration-resistant and metastatic hormone-sensitive)?
Xtandi belongs to the Androgen receptor inhibitor class. Non-steroidal androgen receptor antagonist that blocks androgen binding, nuclear translocation, and DNA interaction This action makes it useful for treating or managing Prostate cancer (castration-resistant and metastatic hormone-sensitive) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Xtandi is the right choice for a specific patient depends on the type and severity of Prostate cancer (castration-resistant and metastatic hormone-sensitive), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Prostate cancer (castration-resistant and metastatic hormone-sensitive)
Common adult dosing range: 160 mg orally once daily. The actual dose for Prostate cancer (castration-resistant and metastatic hormone-sensitive) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Xtandi medicine page.
What to expect
Xtandi treatment for Prostate cancer (castration-resistant and metastatic hormone-sensitive) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Prostate cancer (castration-resistant and metastatic hormone-sensitive)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Xtandi is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Androgen receptor inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Xtandi
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Xtandi full prescribing information · All Androgen receptor inhibitor alternatives
Frequently asked questions
How effective is Xtandi for Prostate cancer (castration-resistant and metastatic hormone-sensitive)?
Effectiveness varies by individual response, dose, and severity. Xtandi is one of several treatment options for Prostate cancer (castration-resistant and metastatic hormone-sensitive), supported by clinical evidence within the androgen receptor inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Xtandi for Prostate cancer (castration-resistant and metastatic hormone-sensitive)?
Treatment duration depends on the nature of Prostate cancer (castration-resistant and metastatic hormone-sensitive) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Xtandi when used for Prostate cancer (castration-resistant and metastatic hormone-sensitive)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Xtandi for Prostate cancer (castration-resistant and metastatic hormone-sensitive)?
Yes. Multiple medicines and non-drug options exist for Prostate cancer (castration-resistant and metastatic hormone-sensitive). Alternatives within the androgen receptor inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.